Involvement of hypothalamic neuropeptide Y in regulating the amphetamine-induced appetite suppression in streptozotocin diabetic rats.

Department of Physiology, Chung Shan Medical University, Taichung 40201, Taiwan, ROC.
Regulatory Peptides (Impact Factor: 2.01). 05/2005; 127(1-3):19-26. DOI: 10.1016/j.regpep.2004.10.008
Source: PubMed

ABSTRACT Amphetamine (AMPH) is a well-known anorectic agent. In normal rats, AMPH-induced anorexia has been attributed to its inhibitory action on hypothalamic neuropeptide Y (NPY), an appetite stimulant in the brain. In diabetic rats, however, if this anorectic response of AMPH might still be observed was uncertain.
Rats (including normal, diabetic and insulin-treated diabetic rats) were given daily with saline or AMPH for 6 days. Changes in food intake, plasma glucose level (PGL) and NPY content of these rats were measured and compared.
The AMPH-induced anorectic response was altered in diabetic rats. Although the anorectic effects of AMPH on the first day of dosing were similar between diabetic and control rats, diabetic rats developed tolerance to this anorexia more rapidly than control rats. This alteration was independent of PGL since PGL levels were not changed following AMPH treatment and PGL normalization induced by phlorizin could not restore the level of AMPH anorexia. On the other hand, this alteration was dependent on the action of NPY because NPY contents were decreased following AMPH treatment and the replacement of insulin in diabetic rats could restore both NPY content and AMPH anorexia.
These results suggested that the elevated hypothalamic NPY content in diabetic rats was involved in modifying the anorectic response of AMPH.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and PurposeAmphetamine (AMPH)-induced appetite suppression has been attributed to its inhibition on neuropeptide Y (NPY) neurons and activation on proopiomelanocortin (POMC) neurons in the hypothalamus. This study examined whether signal transducer and activator of transcription-3 (STAT3) was involved in AMPH's action. Experimental ApproachRats were given AMPH daily for four days. Changes in the expression of NPY, POMC, melanocortin receptor 3 (MC3R), phosphatidylinositol 3-kinase (PI3K), and STAT3 were assessed and compared. Key ResultsResults showed that the expression of NPY decreased with the biggest reduction on Day 2 during AMPH treatment. Alternatively, the expression of POMC, MC3R, PI3K, and STAT3 increased with a maximum response on Day 2. Moreover, pSTAT3/DNA binding activity increased and was expressed in a pattern similar to POMC, MC3R, and PI3K expression. The intracerebroventricular infusion of STAT3 antisense was performed at 60 min before AMPH treatment. This infusion could partially block AMPH-induced anorexia and modulate the expression of NPY, POMC, MC3R, and PI3K, indicating the involvement of STAT3 in AMPH-treated rats. Conclusions and ImplicationsThe results suggest that hypothalamic PI3K-STAT3 signalling participates in regulating NPY- and POMC-mediated appetite suppression and may advance the medical research of anorectic drugs.
    British Journal of Pharmacology 03/2014; 171(13). DOI:10.1111/bph.12667 · 5.07 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is a serious worldwide health problem, affecting 20-40% of the population in several countries. According to animal models, obesity is related to changes in the expression of proteins that control energy homeostasis and in neurotransmission associated to regulation of food intake. For example, it has been reported that diet-induced obesity produced overexpression of dopamine D4 receptor (D4R) mRNA in the ventromedial hypothalamic nucleus (VMH) of mice. Neurons in the VMH sent dense glutamatergic projections to other hypothalamic regions as the paraventricular nucleus (PVN), where multiple signals are integrated to finely regulate energy homeostasis and food intake. Although it is well established that dopaminergic transmission in the hypothalamus plays a key role in modulating feeding, the specific mechanisms involved in the activation of D4R in the PVN and its modulatory action on glutamate release and feeding behavior have remained unexplored. To fill this gap, we characterize the behavioral and neurochemical role of D4R in the PVN. We found that activation of D4R in the PVN induced inhibition of glutamate release and stimulated food intake by inhibiting satiety. Furthermore, activation of D4R in the PVN decreased plasma levels of corticosterone, and this effect was reverted by NMDA. According to our findings, D4R in the PVN may be a target for the pharmacotherapy for obesity as well as eating disorder patients who show restrictive patterns and overweight.
    Physiology & Behavior 06/2014; DOI:10.1016/j.physbeh.2014.04.040 · 3.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amphetamine (AMPH)-induced appetite suppression has been attributed to its inhibition of neuropeptide Y (NPY)-containing neurons in the hypothalamus. This study examined whether hypothalamic cocaine- and amphetamine-regulated transcript (CART)-containing neurons and NPY Y1 receptor (Y1R) were involved in the action of AMPH. Rats were treated daily with AMPH for four days, and changes in feeding behavior and expression levels of NPY, CART, and POMC were assessed and compared. The results showed that both feeding behavior and NPY expression decreased during AMPH treatment, with the biggest reduction occurring on Day 2. By contrast, the expression of CART and melanocortin 3 receptor (MC3R), a member of the POMC neurotransmission, increased with the maximum response on Day 2, directly opposite to the NPY expression results. The intracerebroventricular infusion of NPY antisense or Y1R inhibitor both modulated AMPH-induced anorexia and the expression levels of MC3R and CART. The results suggest that in the hypothalamus both POMC- and CART-containing neurons participate in regulating NPY-mediated appetite control during AMPH treatment. These results may advance the knowledge of molecular mechanism of anorectic drugs.
    Hormones and Behavior 11/2014; 67. DOI:10.1016/j.yhbeh.2014.11.005 · 4.51 Impact Factor